Medipharm Labs has Q2 2025 operating loss of $3.8M

Executive Summary

• Medipharm Labs Corp. reported Q2 2025 financial results, highlighting a 14% year-over-year revenue increase to $11.8 million and a 50% surge in international medical cannabis revenue.
• The company successfully defended a proxy contest with shareholder support and maintained a strong balance sheet with $10.4 million in cash, largely supported by the $4.5 million divestiture of its Hope, B.C. facility.
• Despite a negative adjusted EBITDA of $600,000 for the quarter due to proxy contest expenses, year-to-date adjusted EBITDA improved significantly, and management remains focused on cost streamlining and international expansion.

Key Details

• Revenue Performance:
  • Q2 2025 Total Revenue: $11.8 million (up 14% or $1.5 million from Q2 2024).
  • International Medical Cannabis Revenue: $6.7 million, representing 57% of total revenue (up 50% year-over-year).
  • Canadian Adult-Use and Wellness Revenue: $1.6 million, up 6% year-over-year and 19% sequentially from Q1 2025.
• Product & Market Expansion:
  • Growth in Canada driven by novel metered dose inhalers and water-soluble drops.
  • Plans to launch metered dose inhalers in international markets including Australia and the United Kingdom.
• Profitability & Expenses:
  • Gross Profit: $3.3 million (28% of revenue), down from prior periods due to product mix.
  • Operating Expenses: $4.3 million (down year-over-year and sequentially).
  • Proxy Contest Expense: $2.2 million included in operating expenses.
  • General and Administrative Expenses (excluding proxy contest): Decreased by $800,000 year-over-year.
  • Adjusted EBITDA (Q2 2025): Negative $600,000.
  • Adjusted EBITDA (Year-to-Date): Negative $400,000, improved from negative $1.1 million in H1 2024.
• Balance Sheet & Liquidity:
  • Cash Balance: $10.4 million at end of Q2 2025 (up from $8.4 million in Q1 2025).
  • Cash increase supported by divestiture of Hope, B.C. facility for $4.5 million on June 5, 2025.
  • Company remains virtually debt-free.
  • Owns two production facilities outright with an appraised value of over $15 million.
• Corporate Governance:
  • Shareholders voted three-to-one in support of the board of directors, successfully defending a proxy contest.
• Upcoming Events:
  • Conference call/webcast scheduled for August 14, 2025, at 10:00 a.m. ET.

Notable Quotes

• David Pidduck, CEO: "We are pleased with our strong year-over-year revenue growth and continued momentum in international markets... While the second quarter included the cost and distraction of a proxy contest, our team remained focused and delivered solid results."
• Greg Hunter, CFO: "The second quarter demonstrated the resilience of our commercial strategy... As we move forward, management remains focused on and relentless in driving further revenue growth and continuing to streamline expenses to enhance our profitability profile."